Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hepatitis B virus (HBV) infection, met its primary efficacy endpoint. The data show that Viread is non-inferior to the company's once-daily antiviral drug Hepsera(R) (adefovir dipivoxil) among patients with "e" antigen (HBeAg)-positive chronic hepatitis B. The primary efficacy endpoint, the proportion of patients with a complete response at week 48, was defined by serum HBV DNA levels below 400 copies/mL and histologic improvement characterized by at least a two point reduction in the Knodell necroinflammatory score (a measure of necro-inflammation - an inflammatory process in the liver including or leading to death of liver cells) with no concurrent worsening of fibrosis (scarring of liver tissue).

At 48 weeks, 66.5 percent of patients in the Viread arm (n=176) had a complete response compared to 12.2 percent in the Hepsera arm (n=90; p less than 0.001). The most commonly observed treatment-emergent adverse events of moderate intensity or higher were abdominal pain, back pain, headache, respiratory infections and transaminase elevations. The incidence of these events was comparable between the Viread and Hepsera arms of the study. In addition, the most frequently observed grade 3 or 4 laboratory abnormalities were elevations in transaminase and serum amylase and were comparable between the two arms. Full study results will be submitted for presentation at an upcoming scientific meeting.

Study 103 is the second of two Phase III pivotal studies evaluating the efficacy, safety and tolerability of Viread for the treatment of chronic hepatitis B to have met its primary efficacy endpoint. Earlier this month,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:5/22/2013)... May 22, 2013  Viral hepatitis is an asymptomatic disease ... of those with hepatitis C are unaware they have the ... Awareness Day in the U.S. House of Representatives will take ... Foyer of the Rayburn House Office Building in ... for the Study of Liver Diseases ( AASLD ) is ...
(Date:5/22/2013)... WHITE PLAINS, N.Y. , May 22, 2013 /PRNewswire/ ... $6 million to Valor Biotherapeutics, LLC, a ... completion of pre-clinical development, manufacturing, and a Phase I ... change the poor outcomes faced by many patients with ... with rituximab. Valor,s protein, IGN002, is ...
(Date:5/22/2013)... CAESAREA, Israel , May 22, 2013 ... clinical data presented from the DEFLECT-I study demonstrates that ... brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) ... Heart Scientific Advisory Board announces consensus on the importance ... the importance and need for cerebral protection during cardiovascular ...
Breaking Medicine Technology:Hepatitis Awareness: Bringing Attention to a Silent Epidemic 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 3New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 4
... BETHESDA, Md. , July 22 At two Food ... Vice President, Pharmaceutical Risk Management Services of Pinney ... ensure that Risk Evaluation and Mitigation Strategies (REMS) benefit patient safety ... , ...
... , WOODCLIFF LAKE, N.J. , July 22 Par ... Patrick J. Zenner has been elected to the company,s board of ... Committee and the Corporate Development Review Committee.   , ... Mr. Zenner retired in January 2001 ...
Cached Medicine Technology:Expert Challenges FDA to Bring Predictability, Feasibility, and Transparency to Drug Risk Management Process 2Patrick J. Zenner Elected to Board of Directors of Par Pharmaceutical Companies, Inc. 2
(Date:5/22/2013)... May 22, 2013 Hurricane preparation isn’t ... home. That’s why Amica Insurance is reminding ... the upcoming hurricane season. , “An important part of ... Cook, a senior assistant vice president at Amica Insurance. ... before the threat of a storm.” , Flood damage ...
(Date:5/22/2013)... trustworthy, loving child care is one of the most important ... parents in their search, Paty’s Daycare has launched a ... staff and much more. , “Our new website is vibrant, ... Patricia “Auntie Paty” Sutton, founder of Paty’s Daycare. “Just as ... from the first time that you walk through the front ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Unknown to the ... area at 30 mph. Minutes before it struck, the ... the nearing threat. This gave them time to reach safety ... Data is proud to provide a product that will ... A Wheelock SAFEPATH® SP40S Emergency Evacuation System provides ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... who die each year awaiting an organ donation dropped ... numbers of children are receiving donor organs. During ... expanded to include not just patients who,ve experienced brain ... death." But it,s unclear how much that shift ...
(Date:5/22/2013)... oil supplements could help reduce the risk for ... The supplements, also known as omega-3 fatty acids, ... linked to insulin sensitivity, Harvard researchers found. Higher ... also been linked to a lower risk for ... fish oil increased circulating adiponectin, whether similar effects ...
Breaking Medicine News(10 mins):Health News:Reviewing Insurance Policies: a Key Part of Hurricane Preparations 2Health News:Paty’s Daycare Launches New Website to Connect with Parents in Need of Nurturing Child Care 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 2Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 3Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 4Health News:Fish Oil Pills Might Cut Diabetes Risk, Researchers Say 2
... Heart attacks in women go largely unrecognized 30 to ... warning signs and fail or delay getting help, run the ... University and SUNY Upstate Medical University have developed an educational ... ultimately, save lives. Women often don,t have the same ...
... (HealthDay News) -- Two-thirds of driving-age American teens with ... plan to drive, and these teens have a number ... with high-functioning autism spectrum disorders, or HFASDs, have subtle ... They also have difficulty regulating emotions. Many of ...
... (Jan. 12, 2012) Using two cell ... breast cancer lymph node metastases, researchers at Moffitt ... have developed targeted, fluorescent molecular imaging probes that ... The new procedure could spare breast cancer patients ...
... how the brain reconfigures its connections to minimize distractions and ... order to behave efficiently, you want to process relevant sensory ... your current situation," said Joy Geng, assistant professor of psychology ... For example, a flashing road sign alerts us to traffic ...
... , THURSDAY, Jan. 12 (HealthDay News) -- The ... HIV-infected person is the single most important risk factor for ... study of heterosexual couples has found. The research, published ... , also confirmed that the use of condoms significantly reduces ...
... enrollees cost them less, Medicare Advantage plans would profit ... strictly forbids practices such as denying coverage based on ... membership is to design insurance benefits that attract the ... 12, 2012, edition of the New England Journal ...
Cached Medicine News:Health News:Educating women about heart attacks could save lives 2Health News:Educating women about heart attacks could save lives 3Health News:Little Known About How Autism Affects Teen Drivers: Researchers 2Health News:Researchers find new, noninvasive way to identify lymph node metastasis 2Health News:Partner's 'Viral Load' a Major Factor in HIV Transmission: Study 2Health News:Gym benefits help Medicare plans recruit healthy seniors 2Health News:Gym benefits help Medicare plans recruit healthy seniors 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: